Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cyclacel appoints Dr Nicholas Bacopoulos to Board

This article was originally published in Scrip

Executive Summary

Cyclacel Pharmaceuticals, a US biopharmaceutical company discovering, developing and commercialising mechanism-targeted drugs to treat cancer and other serious disorders, has appointed Dr Nicholas Bacopoulos to its board of directors. Dr Bacopoulos's previous leadership roles include CEO and president of Aton Pharma (a company subsequently acquired by Merck), where he led the development of Zolinza. He was formerly president and head of R&D at OSI Pharmaceuticals, where he was involved with the global development of Tarceva, approved for the treatment of non-small cell lung and pancreatic cancers.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts